EyePoint Pharmaceuticals' CEO will discuss the company's retinal disease therapies at the Guggenheim SMID Cap Biotech Conference.
Quiver AI Summary
EyePoint Pharmaceuticals, Inc. announced that its President and CEO, Dr. Jay S. Duker, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025. The event will be available for live streaming and later replay on their website. EyePoint, a clinical-stage biopharmaceutical company focused on innovative treatments for serious retinal diseases, is advancing its lead product candidate, DURAVYU™ (EYP-1901), which is undergoing Phase 3 clinical trials for wet age-related macular degeneration and Phase 2 trials for diabetic macular edema. The company expects to release topline data for the Phase 2 trial in early 2025 and for the Phase 3 trials in 2026. EyePoint utilizes its proprietary Durasert E™ technology for sustained drug delivery and is headquartered in Watertown, Massachusetts.
Potential Positives
- Participation of the CEO in a prominent industry conference indicates strong leadership engagement and visibility for EyePoint Pharmaceuticals.
- Progress in clinical trials for DURAVYU™ and EYP-2301 highlights advancements in the company's pipeline targeting serious retinal diseases, potentially leading to future product approvals.
- The company expects to release significant clinical trial data (Q1 2025 for DME and 2026 for wet AMD), which could positively impact investor interest and market perception.
- The proprietary Durasert E™ technology demonstrates a competitive edge in sustained drug delivery, supported by a record of safety in previous FDA-approved products.
Potential Negatives
- The timeline for potential FDA approval of DURAVYU™ is uncertain, which may create concerns among investors regarding the company's future prospects.
- EyePoint Pharmaceuticals is still in the clinical phase with its lead product candidate, indicating a lack of established revenue-generating products at this stage, which may raise investor apprehensions.
- The release does not provide any significant updates on the outcomes of ongoing clinical trials, potentially leading to uncertainty about the effectiveness and viability of the company's pipeline products.
FAQ
What is the date and time of the fireside chat at the Guggenheim Conference?
Jay S. Duker will participate in the fireside chat on February 6, 2025, at 9:30 a.m. ET.
Where can I access the webcast of the fireside chat?
The webcast and archived replay can be accessed on the Investors section of EyePoint's website at www.eyepointpharma.com.
What is DURAVYU and its significance?
DURAVYU™ is an investigational treatment for VEGF-mediated retinal diseases, currently in pivotal Phase 3 trials for wet AMD.
What technology does EyePoint Pharmaceuticals utilize for drug delivery?
EyePoint leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery in its treatments.
What is the expected timeline for data from EyePoint's clinical trials?
Full topline data from the Phase 2 trial in DME is expected in Q1 2025, with Phase 3 data for wet AMD in 2026.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EYPT Insider Trading Activity
$EYPT insiders have traded $EYPT stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $EYPT stock by insiders over the last 6 months:
- KAREN L. ZADEREJ purchased 12,500 shares for an estimated $99,750
- GORAN ANDO purchased 5,000 shares for an estimated $39,750
- NANCY LURKER purchased 3,173 shares for an estimated $25,003
- WENDY F DICICCO purchased 2,567 shares for an estimated $19,996
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$EYPT Hedge Fund Activity
We have seen 69 institutional investors add shares of $EYPT stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FEDERATED HERMES, INC. added 1,633,468 shares (+562.9%) to their portfolio in Q3 2024, for an estimated $13,051,409
- PATIENT SQUARE CAPITAL LP added 1,361,979 shares (+inf%) to their portfolio in Q3 2024, for an estimated $10,882,212
- 5AM VENTURE MANAGEMENT, LLC added 1,000,000 shares (+2000.0%) to their portfolio in Q3 2024, for an estimated $7,990,000
- AMERIPRISE FINANCIAL INC removed 897,032 shares (-97.3%) from their portfolio in Q3 2024, for an estimated $7,167,285
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 877,790 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $7,013,542
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 802,809 shares (-38.8%) from their portfolio in Q3 2024, for an estimated $6,414,443
- FIERA CAPITAL CORP removed 677,038 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $5,409,533
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 9:30 a.m. ET.
A webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com .
About EyePoint Pharmaceuticals
EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E ™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU ™ (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E ™ . DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in diabetic macular edema (DME). EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026.
Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E ™ to potentially improve outcomes in serious retinal diseases. The proven Durasert ® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Christina Tartaglia
Precision AQ
Direct: 212-698-8700
[email protected]
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
[email protected]